The changing treatment options for CMV retinitis.
Gilden
D
D
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use; D000077404:Cidofovir; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000276:immunology; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004343:Drug Implants / Q000009:adverse effects; D004352:Drug Resistance, Microbial; D017245:Foscarnet / Q000009:adverse effects / Q000627:therapeutic use*; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018655:Lymphocyte Count; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D013873:Thionucleotides
D000998:Antiviral Agents; D004343:Drug Implants; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D013873:Thionucleotides; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir; C091346:fomivirsen